Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
Date:11/15/2010

CRANBURY, N.J., Nov. 15, 2010 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company dedicated to the development of peptide mimetic and small molecule agonist compounds with a focus on melanocortin and natriuretic peptide receptor systems, today announced results for its first quarter ended September 30, 2010. Palatin reported a net loss of $4.6 million, or $(0.39) per basic and diluted share, for the quarter ended September 30, 2010, compared to a net loss of $37,000, or $(0.00) per basic and diluted share, for the same period in 2009.

The increase in net loss for the quarter ended September 30, 2010, compared to the same period last fiscal year, was primarily attributable to a decrease in revenue recognized under Palatin's research collaboration and license and clinical trial agreements with AstraZeneca AB (AstraZeneca) as a result of successful completion of the research collaboration portion of the agreements.

REVENUERevenues for the quarter ended September 30, 2010 were $216,000, compared to $3.7 million for the same period in 2009, reflecting the decrease in revenue recognized under Palatin's agreements with AstraZeneca.

COSTS AND EXPENSESTotal operating expenses for the quarter ended September 30, 2010 were $4.8 million, compared to $3.8 million for the comparable quarter of 2009. The increase in operating expenses for the quarter was primarily due to Palatin's recognition of severance related expenses of $748,000 in the three months ended September 30, 2010 pursuant to Palatin's previously disclosed realignment of resources.

CASH POSITION / GOING CONCERNPalatin's cash, cash equivalents and investments were $4.7 million as of September 30, 2010, compared to $8.9 million at June 30, 2010.  Palatin's Quarterly Report on Form 10-Q filed on November 15, 2010, contains going concern disclosures,
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
2. Palatin Announces Strategic Realignment of Operations
3. Palatin Technologies, Inc. to Raise $2.0 Million Dollars in Registered Direct Offering
4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on February 16, 2010
5. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
6. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2010 Results; Teleconference and Webcast to be held on November 16, 2009
7. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2009 Results; Teleconference and Webcast to be held on September 8, 2009
8. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
9. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
10. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
11. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Pipette.com has added ... to their comprehensive portfolio of Eppendorf products. , The ... purchase a Centrifuge 5424/5424 R and receive the following:, ... Eppendorf Research plus or Eppendorf Reference 2 , ...
(Date:1/22/2015)... Diagenode, Inc., a leading global ... and complete solutions for epigenetics research, recently launched ... the need for manual processing. The new ChIPettor ... of histones or transcription factors and a semi-automated ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... provides hope ... for combating problems of resistance -, PALO ALTO, ... today announced that they have entered,into a worldwide strategic ... for viral and bacterial diseases. The,collaboration provides GlaxoSmithKline access ...
... 8 Debiopharm Group,(Debiopharm), a global independent ... conditions, presented Professors Minoru,Toyota and Keiichi Nakayama ... oncology research work. The Awards were presented ... Conference of the JCA in Yokohama,Japan, by ...
... Ill. --- An innovative and inexpensive way of ... in novel forms of advanced materials that pave ... The new fabrication technique, known as soft lithography, ... the ability to scale-up the manufacturing process to ...
Cached Biology Technology:GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 2GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 3GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 4GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 5Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award 2Nanofabrication method paves way for new optical devices 2
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3The Global Watermarking and Fingerprinting Markets 2
... While the costs associated with storing nuclear waste and ... legitimate concerns, they may no longer be obstacles on ... by researchers at the University of Notre Dame, led ... geological sciences and concurrent professor of chemistry and biochemistry, ...
... flowing through Venice,s famous canals laps at buildings a little ... rising sea level. Although previous studies had found that Venice ... to slowly sink, and even to tilt slightly to the ... a rate of about 2 millimeters a year," said Yehuda ...
... the BP Deepwater Horizon drilling rig in the Gulf of ... understand the impact that this disaster has had on the ... a rate of approximately 53,000 barrels per day before the ... confirms that oil from the Macondo well made it into ...
Cached Biology News:New paper by Notre Dame researchers describes method for cleaning up nuclear waste 2AGU: Venice hasn't stopped sinking after all 2AGU: Venice hasn't stopped sinking after all 3AGU: Venice hasn't stopped sinking after all 4Study confirms oil from Deepwater Horizon disaster entered food chain in the Gulf of Mexico 2
... endotoxin-free plasmid DNA preparations are prepared ... quantities from 1mg to multi-gram scales. ... customer needs, and glycerol stocks are ... Transformation, clonal selection (Clonal selection includes ...
... 16-independent channels for automated gigaseal patch clamping. ... against voltage-gated ion channels, such as hERG ... The four pipette heads afford more ... channel drug discovery. The glass-coated tunnels ...
... systems need to be able to handle larger ... ports, as well as interface with telemetry systems. ... more, particularly with dogs, pigs, and primates. ... starting time, and the computer can be located ...
... Antibody Plate is a 96-well ELISA-compatible ... This antibody (mouse IgG 1 ) ... glutathione-S-transferase (GST), and binds with ... fusion protein in which the tag ...
Biology Products: